{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:27:04Z","timestamp":1788294424391,"version":"build-2803163510"},"reference-count":44,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,5,26]]},"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Different studies have been conducted on the role of curcumin in health since having multiple properties, including antioxidant and anti-inflammatory effects. Due to the lack of studies regarding curcumin effects on obese patients with non-alcoholic fatty liver disease (NAFLD), our protocol was designed to assess nanocurcumin impacts on blood sugar, lipids, inflammatory indices, insulin resistance and liver function, especially by nesfatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>This trial will be conducted in the Oil Company central hospital of Tehran, Iran with a primary level of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>84 obese patients with NAFLD diagnosed using ultrasonography will be employed according to the eligibility criteria\u200e.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>The patients will be randomly divided into two equal groups (nanocurcumin and placebo, two 40\u2009mg capsules per day with meals for 3\u2009months, follow-up monthly). Also, lifestyle changes (low-calorie diet and physical activity) will be advised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measures of the primary and secondary outcomes<\/jats:title>\n                    <jats:p>A general questionnaire, 24\u2009hours food recall (at the beginning, middle and end) and short-form International Physical Activity Questionnaire will be completed. Blood pressure, anthropometrics, serum sugar indices (fasting blood sugar and insulin, insulin resistance and sensitivity and glycosylated haemoglobin), lipids (triglyceride, total cholesterol and low-density and high-density lipoprotein-cholesterol, inflammatory profiles (interleukin-6, high-sensitivity C-reactive protein, and tumour necrosis factor-alpha), liver function (alanine and aspartate transaminase) and nesfatin will be measured at the beginning and end of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This trial would be the first experiment to determine nanocurcumin efficacy on certain blood factors among obese patients with NAFLD. Nevertheless, studying the potential consequences of curcumin in various diseases, especially NAFLD, is required for clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>IRCT2016071915536N3; pre-results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-016914","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T20:10:16Z","timestamp":1499803816000},"page":"e016914","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol"],"prefix":"10.1136","volume":"7","author":[{"given":"Seyed Ali","family":"Jazayeri-Tehrani","sequence":"first","affiliation":[{"name":"Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, International Campus, Tehran University of Medical Sciences (IC-TUMS), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mahdi","family":"Rezayat","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Department of Toxicology\u2013Pharmacology, Faculty of Pharmacy, Pharmaceutical Science Branch, Islamic Azad University (IAUPS), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siavash","family":"Mansouri","sequence":"additional","affiliation":[{"name":"National Iranian Oil Company (NIOC) Central Hospital, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Qorbani","sequence":"additional","affiliation":[{"name":"Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Moayed","family":"Alavian","sequence":"additional","affiliation":[{"name":"Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatollah University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Daneshi-Maskooni","sequence":"additional","affiliation":[{"name":"Department of Community Nutrition, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Javad","family":"Hosseinzadeh-Attar","sequence":"additional","affiliation":[{"name":"Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, International Campus, Tehran University of Medical Sciences (IC-TUMS), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"2025121223132062000_7.7.e016914.1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23280"},{"key":"2025121223132062000_7.7.e016914.2","first-page":"9026","article-title":"Role of liver biopsy in nonalcoholic fatty liver disease","volume":"20","author":"Nalbantoglu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2025121223132062000_7.7.e016914.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.5370"},{"key":"2025121223132062000_7.7.e016914.4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.193"},{"key":"2025121223132062000_7.7.e016914.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04556.x"},{"key":"2025121223132062000_7.7.e016914.6","unstructured":"Kasper D , Fauci A , Hauser S , et al . Harrison's principles of internal medicine, 19e. Mcgraw-hill 2015."},{"key":"2025121223132062000_7.7.e016914.7","first-page":"1275","article-title":"Prevalence of Non-Alcoholic Fatty liver disease and its Predictors in North of Iran","volume":"43","author":"Amirkalali","year":"2014","journal-title":"Iran J Public Health"},{"key":"2025121223132062000_7.7.e016914.8","first-page":"e9248","article-title":"Non alcoholic fatty liver disease in southern Iran: a population based study","volume":"13","author":"Lankarani","year":"2013","journal-title":"Hepat Mon"},{"key":"2025121223132062000_7.7.e016914.9","doi-asserted-by":"crossref","first-page":"e25128","DOI":"10.5812\/jjcdc.25128","article-title":"Prevalence of Non-Alcoholic Fatty liver disease in morbidly obese patients undergoing Sleeve Bariatric Surgery in Iran and Association with other Comorbid Conditions","volume":"4","author":"Karimi Sari","year":"2015","journal-title":"Jundishapur Journal of Chronic Disease Care"},{"key":"2025121223132062000_7.7.e016914.10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4236\/ojmi.2013.33015","article-title":"Association between Nonalcoholic Fatty liver disease (NAFLD) and coronary artery disease (CAD) in patients with Angina Pectoris","volume":"03","author":"Adibi","year":"2013","journal-title":"Open Journal of Medical Imaging"},{"key":"2025121223132062000_7.7.e016914.11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00535-014-0948-9","article-title":"Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012","volume":"50","author":"Nishioji","year":"2015","journal-title":"J Gastroenterol"},{"key":"2025121223132062000_7.7.e016914.12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3748\/wjg.v17.i2.271","article-title":"Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease","volume":"17","author":"Sahebkar","year":"2011","journal-title":"World J Gastroenterol"},{"key":"2025121223132062000_7.7.e016914.13","unstructured":"National Guideline Centre (UK). Non-Alcoholic Fatty liver disease: assessment and Management. London: National Institute for Health and Care Excellence (UK), 2016. (NICE Guideline, No. 49.) 5, Risk factors for NAFLD. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK384735\/"},{"key":"2025121223132062000_7.7.e016914.14","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i40.6911"},{"key":"2025121223132062000_7.7.e016914.15","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/864946"},{"key":"2025121223132062000_7.7.e016914.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2013.11.003"},{"key":"2025121223132062000_7.7.e016914.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.01.001"},{"key":"2025121223132062000_7.7.e016914.18","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/810961"},{"key":"2025121223132062000_7.7.e016914.19","doi-asserted-by":"publisher","DOI":"10.1080\/00365520802588133"},{"key":"2025121223132062000_7.7.e016914.20","article-title":"Nesfatin-1 and its effects on different systems","volume":"19","author":"Ayada","year":"2015","journal-title":"Hippokratia"},{"key":"2025121223132062000_7.7.e016914.21","doi-asserted-by":"publisher","DOI":"10.3109\/00365513.2012.699097"},{"key":"2025121223132062000_7.7.e016914.22","doi-asserted-by":"crossref","unstructured":"Shadab Siddiqui M , Sanyal AJ . Nonalcoholic fatty liver disease. Yamada's Atlas of Gastroenterology. 2016;35:428.","DOI":"10.1002\/9781118512104.ch53"},{"key":"2025121223132062000_7.7.e016914.23","doi-asserted-by":"crossref","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2014","journal-title":"Nature reviews. Disease primers"},{"key":"2025121223132062000_7.7.e016914.24","doi-asserted-by":"publisher","DOI":"10.1542\/pir.36-5-198"},{"key":"2025121223132062000_7.7.e016914.25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-0035-1562941","article-title":"Foreword. Nonalcoholic Fatty Liver Disease","volume":"35","author":"Day","year":"2015","journal-title":"Semin Liver Dis"},{"key":"2025121223132062000_7.7.e016914.26","doi-asserted-by":"publisher","DOI":"10.18043\/ncm.77.3.216"},{"key":"2025121223132062000_7.7.e016914.27","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.126"},{"key":"2025121223132062000_7.7.e016914.28","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i29.3377"},{"key":"2025121223132062000_7.7.e016914.29","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4254\/wjh.v7.i2.204","article-title":"Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease","volume":"7","author":"Eslamparast","year":"2015","journal-title":"World J Hepatol"},{"key":"2025121223132062000_7.7.e016914.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0810291"},{"key":"2025121223132062000_7.7.e016914.31","first-page":"18","article-title":"Curcumin: a review","volume":"2","author":"Chauhan","year":"2014","journal-title":"Journal of Applied Pharmaceutical Research"},{"key":"2025121223132062000_7.7.e016914.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.03.025"},{"key":"2025121223132062000_7.7.e016914.33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/898361","article-title":"Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial","volume":"2014","author":"Ganjali","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"2025121223132062000_7.7.e016914.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1673-1"},{"key":"2025121223132062000_7.7.e016914.35","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2012.012040"},{"key":"2025121223132062000_7.7.e016914.36","first-page":"18","article-title":"The effect of curcumin on serum level of aspartate and alanine amoinotransferase and cardiac level of oxidative stress markers in diabetic rats","volume":"17","author":"Roghani Dehkordi","year":"2012","journal-title":"Pejouhandeh"},{"key":"2025121223132062000_7.7.e016914.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-011-0188-1"},{"key":"2025121223132062000_7.7.e016914.38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bcpt.12076","article-title":"Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase","volume":"113","author":"Um","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025121223132062000_7.7.e016914.39","first-page":"249","article-title":"Curcumin: therapeutical potential in ophthalmology","volume":"80","author":"Pescosolido","year":"2014","journal-title":"Planta Med"},{"key":"2025121223132062000_7.7.e016914.40","first-page":"887","article-title":"Effect of Oral Curcumin Administration on insulin resistance, serum resistin and Fetuin-A in Obese Children: randomized Placebo-Controlled Study","volume":"5","author":"Abdallah Ismail","year":"2014","journal-title":"RJPBCS"},{"key":"2025121223132062000_7.7.e016914.41","doi-asserted-by":"crossref","first-page":"89369","DOI":"10.1155\/2007\/89369","article-title":"Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-gamma Activation","volume":"2007","author":"Jacob","year":"2007","journal-title":"PPAR Res"},{"key":"2025121223132062000_7.7.e016914.42","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/403251"},{"key":"2025121223132062000_7.7.e016914.43","first-page":"2097","article-title":"Biological and anticancer effects of curcumin","volume":"31","author":"Kamali","year":"2014","journal-title":"J Isfahan Med Sch"},{"key":"2025121223132062000_7.7.e016914.44","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0116"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-016914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:13:31Z","timestamp":1765610011000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-016914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,10]]},"published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1136\/bmjopen-2017-016914"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-016914","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}